Recent years have witnessed significant developments in the field of diabetes treatment, with a particular focus on GLP-1 receptor agonists. Among these novel therapies, retatrutide and trizepatide are emerging as https://laraiwto643364.activosblog.com/37649731/exploring-the-future-of-type-2-diabetes-treatment-retatrutide-and-trizepatide